| Drug Name |
Dienogest |
| Drug ID |
BADD_D02619 |
| Description |
Dienogest is an orally-active semisynthetic progestogen which also possesses the properties of 17α-hydroxyprogesterone. It is a derivative of 19-nortestosterone and has antiandrogenic properties. It is primarily used as a contraceptive in combination with ethinylestradiol, or in other combination form pills approved in United States and Europe however it is not available in the US by itself. In Europe, Australia, Malaysia, Singapore and Japan, dienogest single therapy is an approved treatment for endometriosis to alleviate painful symptoms of endometriosis and reduce endometriotic lesions [A20330]. Dienogest is commonly marketed as Visanne, Natazia and Qlaira. |
| Indications and Usage |
Indicated for use as the treatment of endometriosis alone and as a contraceptive in combination with ethinylestradiol. |
| Marketing Status |
approved |
| ATC Code |
G03DB08 |
| DrugBank ID |
DB09123
|
| KEGG ID |
D03799
|
| MeSH ID |
C023635
|
| PubChem ID |
68861
|
| TTD Drug ID |
D04CBI
|
| NDC Product Code |
77382-0130; 24002-0034; 63190-0270 |
| UNII |
46M3EV8HHE
|
| Synonyms |
dienogest | 17 alpha-cyanomethyl-17 beta-hydroxy-13 beta-methylgona-4,9-dien-3-one | 17 alpha-cyanomethyl-17 beta-hydroxyestra-4,9(10)-diene-3-one | 19-norpregna-4,9-diene-21-nitrile, 17-hydroxy-3-oxo-, (17alpha)- | STS 557 | STS-557 |
